Study wrapper · #436
Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.
Editor's note
A small observational cohort (34 patients) testing tirzepatide in people who regained weight after bariatric surgery or endoscopic therapy. Over 24 weeks on weekly tirzepatide (2.5–10 mg), mean total body weight loss was 18.1% with reduced waist circumference; adverse events were gastrointestinal (constipation, diarrhea, nausea), described as generally mild and not leading to discontinuation. The finding is encouraging for a real clinical gap, but the design is the main caveat: no control group, a single arm, only 34 patients, and just 24 weeks. Without a comparator we cannot separate the drug's effect from expectation or concurrent behavior change, and durability beyond six months is unknown. The authors frame it as preliminary. Weight this as a hypothesis-supporting pilot signal in a specific post-surgical population, consistent with tirzepatide's broader weight-loss data but far from confirmatory on its own.
Plain-language abstract
Some people regain weight after weight-loss surgery, and options are limited. This small study followed 34 such patients (26 women, 8 men) who were given tirzepatide, a weekly injection, at doses from 2.5 to 10 mg. After 24 weeks, they had lost about 18% of their body weight on average and their waistlines shrank significantly, with most moving into a lower weight category. Side effects were limited to stomach and bowel problems such as constipation, diarrhea and nausea; these were generally mild and none of the patients stopped treatment because of them. The researchers describe the results as promising but preliminary. Because there was no comparison group and only a small number of patients followed for a fairly short time, the study cannot firmly establish how well tirzepatide works in this situation or whether the weight loss lasts. The authors suggest it may be a useful non-surgical option worth studying further.